MARKET

SAGE

SAGE

SAGE
NASDAQ

Real-time Quotes | Nasdaq Last Sale

76.98
+6.33
+8.96%
After Hours: 77.14 +0.16 +0.21% 16:00 03/05 EST
OPEN
71.00
PREV CLOSE
70.65
HIGH
77.17
LOW
68.23
VOLUME
641.34K
TURNOVER
--
52 WEEK HIGH
98.39
52 WEEK LOW
25.01
MARKET CAP
4.49B
P/E (TTM)
6.73
1D
5D
1M
3M
1Y
5Y
Top Growth Stocks for March 2021
These are the top stocks for EPS and sales growth for March 2021.
Investopedia · 2d ago
DJ Sage Therapeutics Is Maintained at Equal-Weight by Morgan Stanley
Dow Jones · 4d ago
DJ Sage Therapeutics Price Target Raised to $87.00/Share From $83.00 by Morgan Stanley
Dow Jones · 4d ago
Morgan Stanley Maintains Equal-Weight on Sage Therapeutics, Raises Price Target to $87
Morgan Stanley analyst Matthew Harrison maintains Sage Therapeutics (NASDAQ:SAGE) with a Equal-Weight and raises the price target from $83 to $87.
Benzinga · 4d ago
--Analyst Actions: Morgan Stanley Adjusts Sage Therapeutics PT to $87 From $83, Maintains Equal Weight Rating
MT Newswires · 4d ago
Analysts Offer Insights on Healthcare Companies: SAGE Therapeutics (SAGE) and Paratek Pharmaceuticals (PRTK)
SmarterAnalyst · 5d ago
Premarket analyst action - healthcare
Fate Therapeutics (FATE) initiated with a Buy at BofA Securities. PT set to $115, implies a 33% increase from last price.Wedbush analyst David Nierengarten downgraded FATE to Neutral from Outperform
Seekingalpha · 02/26 14:27
Top Analyst Upgrades and Downgrades: AIG, Best Buy, Carvana, Dell, HP, Monster Beverage, Twitter, Zscaler and More
247WallSt.com · 02/26 13:59
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SAGE. Analyze the recent business situations of SAGE through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 21 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SAGE stock price target is 102.21 with a high estimate of 187.00 and a low estimate of 70.00.
EPS
Institutional Holdings
Institutions: 456
Institutional Holdings: 63.21M
% Owned: 108.27%
Shares Outstanding: 58.38M
TypeInstitutionsShares
Increased
71
6.75M
New
80
-1.04M
Decreased
84
5.59M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.94%
Pharmaceuticals & Medical Research
+1.63%
Key Executives
Chairman/Director
Kevin Starr
Chief Executive Officer/Director
Barry Greene
Chief Financial Officer/Treasurer
Kimi Iguchi
Chief Operating Officer
Michael Cloonan
Senior Vice President/General Counsel/Secretary
Anne Cook
Chief Scientific Officer
Albert Robichaud
Other/Director
Jeffrey Jonas
Other
Stephen Kanes
Independent Director
Elizabeth Barrett
Independent Director
Michael Cola
Independent Director
James Frates
Independent Director
Geno Germano
Independent Director
George Golumbeski
Independent Director
Asha Nayak
Independent Director
Steven Paul
No Data
  • All
  • Financials
  • Insiders
More
About SAGE
SAGE Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company's lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor. The Company's next-generation product candidates, SAGE-217 and SAGE-689, also target the GABAA receptor system. The Company is focused on developing drugs based on selective allosteric modulation of CNS synaptic and extrasynaptic receptors. The Company's chemistry platform is focused on the chemical scaffolds of endogenous or chemically modified synthetic neuroactive steroid compounds that are allosteric modulators of GABAA or N-Methyl-D-aspartic acid or N-Methyl-D-aspartate (NMDA) receptors.

Webull offers kinds of SAGE Therapeutics Inc stock information, including NASDAQ:SAGE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SAGE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SAGE stock methods without spending real money on the virtual paper trading platform.